Eterna Therapeutics Expects to Begin First-in-Human Ovarian Cancer Trial in H2

MT Newswires Live

01/06

Eterna Therapeutics (ERNA) said Tuesday it is on track to initiate its first-in-human ovarian cancer trial in H2 2026.

The company said it recently concluded a pre-investigational new drug application meeting with the US Food and Drug Administration, with feedback from the agency setting a pathway for submitting an investigational new drug application.

Eterna said that following the meeting, it has boosted key operational activities, with tech transfer already underway.

The company said it is currently progressing ERNA-101 therapy for ovarian cancer and ERNA-201 for autoimmune disease.

Ernexa Therapeutics shares were down 4% in recent Tuesday premarket activity.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2601818311"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601818311\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601818311?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601818311","market":"us","top_or_hot":-1,"title":"Eterna Therapeutics Expects to Begin First-in-Human Ovarian Cancer Trial in H2","media":"MT Newswires Live","content":"<html><body><p> Eterna <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ERNA) said Tuesday it is on track to initiate its first-in-human ovarian cancer trial in H2 2026.</p><p>The company said it recently concluded a pre-investigational new drug application meeting with the US Food and Drug Administration, with feedback from the agency setting a pathway for submitting an investigational new drug application.</p><p>Eterna said that following the meeting, it has boosted key operational activities, with tech transfer already underway.</p><p>The company said it is currently progressing ERNA-101 therapy for ovarian cancer and ERNA-201 for autoimmune disease.</p><p>Ernexa Therapeutics shares were down 4% in recent Tuesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eterna Therapeutics Expects to Begin First-in-Human Ovarian Cancer Trial in H2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEterna Therapeutics Expects to Begin First-in-Human Ovarian Cancer Trial in H2\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-06 21:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Eterna <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ERNA) said Tuesday it is on track to initiate its first-in-human ovarian cancer trial in H2 2026.</p><p>The company said it recently concluded a pre-investigational new drug application meeting with the US Food and Drug Administration, with feedback from the agency setting a pathway for submitting an investigational new drug application.</p><p>Eterna said that following the meeting, it has boosted key operational activities, with tech transfer already underway.</p><p>The company said it is currently progressing ERNA-101 therapy for ovarian cancer and ERNA-201 for autoimmune disease.</p><p>Ernexa Therapeutics shares were down 4% in recent Tuesday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2601818311","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601818311","pubTimestamp":1767707652,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Eterna Therapeutics  said Tuesday it is on track to initiate its first-in-human ovarian cancer trial in H2 2026.The company said it recently concluded a pre-investigational new drug application meeting with the US Food and Drug Administration, with feedback from the agency setting a pathway for submitting an investigational new drug application.Eterna said that following the meeting, it has boosted key operational activities, with tech transfer already underway.The company said it is currently progressing ERNA-101 therapy for ovarian cancer and ERNA-201 for autoimmune disease.Ernexa Therapeutics shares were down 4% in recent Tuesday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4139":"生物科技","BK4007":"制药","ERNA":"Eterna Therapeutics Inc.","BK4539":"次新股"},"translate_title":"Eterna Therapeutics预计将于下半年开始首次人体卵巢癌试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERNA":1,"LENZ":1.5},"content_text":"Eterna Therapeutics (ERNA) said Tuesday it is on track to initiate its first-in-human ovarian cancer trial in H2 2026.The company said it recently concluded a pre-investigational new drug application meeting with the US Food and Drug Administration, with feedback from the agency setting a pathway for submitting an investigational new drug application.Eterna said that following the meeting, it has boosted key operational activities, with tech transfer already underway.The company said it is currently progressing ERNA-101 therapy for ovarian cancer and ERNA-201 for autoimmune disease.Ernexa Therapeutics shares were down 4% in recent Tuesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}